Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Massachusetts General Hospital
Biotech
Rival AbbVie and Denali prospects flunk phase 2/3 ALS tests
Neither AbbVie and Calico’s fosigotifator nor Denali’s DNL343 significantly slowed ALS progression, causing misses on the primary endpoints.
Nick Paul Taylor
Jan 7, 2025 5:52am
Patient discharged with eGenesis’ CRISPR-edited pig kidney
Apr 4, 2024 12:27pm
AI tool predicts lung cancer risk in nonsmokers 6 years out
Jan 23, 2023 9:57am
Fujifilm picks up AI program for IVF procedures
Jun 24, 2022 11:38am
Fat could hold key to stem cell treatment for Parkinson's
May 31, 2022 7:30am
Prevencio's AI predicts 1-year heart risks for diabetes patients
Apr 13, 2022 11:00am
